ARTICLE | Company News
Afferon, Icos deal
November 12, 2001 8:00 AM UTC
ICOS exclusively licensed from Afferon worldwide rights to RTX resiniferatoxin to treat urological disorders. ICOS will pay Afferon an upfront license fee, milestones and royalties, and will fund deve...